World Heart — Investor Presentation (August 2011)
32 slides from World Heart's investor presentation, Aug 4, 2011
Slide 1: Investor Presentation
Investor Presentation August 3, 2011
Slide 2: Forward Looking Statements
Forward Looking Statements Statements contained in this presentation, including those pertaining to clinical research, commercialization plans, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that cou
Slide 3: Presenters/Management Team
Presenters/Management Team Name Prior Experience Years Experience Alex Martin Chief Executive Officer Edwards Lifesciences: President, North America Johnson & Johnson (Cordis): SVP, International Morgan Brown EVP & Chief Financial Officer Lifetree Clinical Research: SVP & CFO NPS Pharmaceuticals: VP
Slide 4: WorldHeart Highlights
WorldHeart Highlights Two advanced Ventricular Assist Device programs MiFlow TM VAD – Fully magnetically levitated miniature rotary blood pump; designed to provide long-term circulatory support for earlier-stage heart failure with minimally invasive implant PediaFlow® – Fully magnetically levitated
Slide 5: Heart Failure Device Market Segments
Class I (1.7M) Class II (1.6M) Class III (1.4M) Heart Failure Device Market Segments American College of Cardiology Consensus Report on MCS 2000 for class size. Class IV (0.36M) Resynchronization Therapy Cardiac 100,000 Pts $9 Billion Potential Market BTT LVAD Destination Therapy (DT) 4,000 Pts $360
Slide 6: Market Needs
Market Needs Better Clinical Outcomes Stroke, bleeding, infections and device failures Less invasive implantation Smaller device Non-sternotomy implant Minimal by-pass time Improved user convenience and device interface Easier to use Remote monitoring / diagnostic capabilities Smaller peripherals Fu
Slide 7: Current Technologies Have Not Effectively Addressed Complication Rates
Complication Rates Heartmate II (BTT) 1 Heartmate II (DT) 2 HeartWare (BTT) 3 HeartWare (BTT) (Per Patient Year) 3 Current Technologies Have Not Effectively Addressed Complication Rates 1 – FDA Summary of Safety and Effectiveness Data, 2008. 2 – Slaughter MS, et al. Advanced Heart Failure Treated wi
Slide 8: Recent Article on Acquired von Willebrand Syndrome
Recent Article on Acquired von Willebrand Syndrome Acquired von Willebrand Syndrome in Patients with an Axial Flow Left Ventricular Assist Device Anna L. Meyer, Doris Malehsa, Christoph Bara, Ulrich Budde, Mark S. Slaughter, Axel Haverich and Martin Strueber Circ Heart Fail published online Aug 25,
Slide 9: Recent Article on Acquired von Willebrand Syndrome – cont.
Recent Article on Acquired von Willebrand Syndrome – cont. European Journal of Cardio-thoracic Surgery 35 (2009) 1091-1093 Case Report Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device Doris Malehsa, Anna L. Meyer, Christoph Bara, Mart
Slide 10: Preliminary Results of Independent Investigator Biomarker Study
Preliminary Results of Independent Investigator Biomarker Study 1 PRE ON LVAD ON VAD ON LVAD ON LVAD POST Levacor ® - Preliminary Performance Evaluation In Independent Investigator Biomarker Study The blood handling characteristics of Levacor ® demonstrate reduced impact on von Willebrand Factor (“V
Slide 11: Proprietary Product Design
Proprietary Product Design 2nd Generation 3rd Generation 4th Generation Axial Flow Pumps (~10,000 rpm) Jarvik (Jarvik Heart) HeartMate II (Thoratec) Centrifugal Flow Pump (2 – 3,000 rpm) HVAD (HeartWare) DuraHeart (Terumo) * Next Gen Devices MVAD (Heartware) Heartmate III (Thoratec) Heartmate X (Tho
Slide 12: MiFlow Overview
MiFlow™ Overview MiFlow VAD is Designed with Following Key Features: Fully magnetically levitated rotor Miniaturized profile (approximately the size of a AA battery) Wide operating range (2 L/min to 6 L/min) Pump integrated within inflow cannula tip Minimal blood / device surface interface Innovativ
Slide 13: Key Features
Key Features Fully magnetically levitated rotor: Designed for optimized flow path (wide clearances and reduced shear rates) Designed to improved blood handling (bleeding, pump thrombosis and strokes) Designed to preserve von Willebrand factor Miniaturized Profile Designed to allow non-sternotomy pla
Slide 14: Key Features
Key Features Pump integrated within inflow cannula tip Designed to significantly reduce inflow path surface area Designed to improve device placement and orientation Minimal blood / device surface interface Designed to minimize foreign body blood interaction and inflammatory response Innovative peri
Slide 15: PediaFlow VAD (Basis for MiFlow VAD)
PediaFlow VAD (Basis for MiFlow VAD) Small size Full magnetic levitation Simplest (single axis) Bearingless No wear mechanisms Simple blood path (no secondary flow path) Inflow Outflow Rotor Stator blades Impellor blades
Slide 16: PediaFlow Prototype Development
PediaFlow Prototype Development PF1 – Proof of principle Implants to 17 days PF2 – Hemodynamic optimization Implants to 70 days PF3 – Miniaturized pump Implant of 72 days
Slide 17: In Vivo Results – PF1
In Vivo Results – PF1 Post-explant device analysis First chronic animal study – 6 Days No thrombus deposition on pump surfaces Impeller Blades Stator vanes Pump Housing
Slide 18: In Vivo Results – PF2
In Vivo Results – PF2 Hemolysis Fibrinogen
Slide 19: In Vivo Results – PF2
In Vivo Results – PF2 Platelet Activation Pump implant Sham surgery
Slide 20: PediaFlow/MiFlow – Blood Damage Modeling
PediaFlow/MiFlow – Blood Damage Modeling *Scaled from NIH measurements
Slide 21: In Vivo Results – PF3
In Vivo Results – PF3 Post-explant device analysis Implant duration – 72 Days No deposition on pump surfaces; kidneys free of infarcts
Slide 22: Blood Path Comparison
VAD Blood-Contacting Area (cm 2 ) Priming Volume (ml) Annular Gap Cross-section (mm 2 ) Blood Path Comparison Levacor 20.7 -- MiFlow 3.4 PediaFlow PF3 2.3 MiFlow and PediaFlow PF4 rotors (SLA components for in vitro testing) - Blood paths for PediaFlow and MiFlow are similar
Slide 23: MiFlow Miniaturized VAD - Pump Cross-Section
MiFlow Miniaturized VAD - Pump Cross-Section Inflow Outflow Stator blades Permanent magnet radial support Motor stator Voice coil Motor magnets Axial magnets Impellor blades
Slide 24: Streamlines
Streamlines Miniaturized VAD – CFD Evaluation Q=5.0L/min, 14K rpm
Slide 25: MiFlow – Size Comparison
MiFlow – Size Comparison HeartMate II MiFlow 19 mm 21 mm
Slide 26: MiFlow – Size Comparison
MiFlow – Size Comparison 19 mm 21 mm 21 mm 25 mm HeartMate II HVAD Jarvik 2000 MiFlow 63 cc, 281 gms 50 cc, 145 gms 25 cc, 90 gms 20 cc, 65 gms
Slide 27: Miniaturized VAD Configuration – w/ perc lead
Minaturized VAD Configuration – w/ perc lead Outflow to descending aorta Experience with Jarvik 2000 1,2 validates this anatomic placement 1- Frazier OH. Implantation of the Jarvik 2000 LVAD without use of CPB. Ann Thor Surg 2003:75:1028-30 2-Selzman HC. Off-Pump Insertion of the Jarvik 2000 LVAD. C
Slide 28: Development Timeline – MiFlow VAD
Development Timeline – MiFlow VAD Development costs estimated to $35M (perc lead configuration)
Slide 29: Financial Summary
Financial Summary Cash Balance (3/31/11) $17.7M Monthly Cash Burn $1.2M-$1.3M 52 Week Stock Price (High and Low) * $3.26-$.45 Shares Outstanding 26.7M Options Outstanding 2.1M Warrants Outstanding 13.3M * As of 8/1/11
Slide 30: Strong Intellectual Property Protection
Strong Intellectual Property Protection Strong IP position for single-active axis Maglev rotary pump IP focused on latest-generation technologies (bearingless, magnetically levitated/driven) Rotary pumps (Levacor, PediaFlow, MiFlow) – 15 issued patents (13 owned or exclusively licensed, 2 non-exclus
Slide 31: WorldHeart Highlights
WorldHeart Highlights Two advanced Ventricular Assist Device programs MiFlow TM VAD – Fully magnetically levitated miniature rotary blood pump; designed to provide long-term circulatory support for earlier-stage heart failure with minimally invasive implant PediaFlow® – Fully magnetically levitated
Slide 32: End
End